Allecra Theraps Drug Patent Portfolio
Allecra Theraps owns 1 orange book drug protected by 2 US patents Given below is the list of Allecra Theraps's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US11124526 | Crystalline beta-lactamase inhibitor | 07 Nov, 2034 | Active |
US7687488 | 2-substituted methyl penam derivatives | 03 Dec, 2027 | Active |
Latest Legal Activities on Allecra Theraps's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Allecra Theraps.
Activity | Date | Patent Number |
---|---|---|
Change in Power of Attorney (May Include Associate POA)
Critical
| 03 Jul, 2024 | US7687488 |
Email Notification
Critical
| 03 Jul, 2024 | US7687488 |
Initial letter Re: PTE Application to regulating agency | 25 Apr, 2024 | US7687488 |
Initial letter Re: PTE Application to regulating agency | 25 Apr, 2024 | US11124526 |
Requirement for information sent under 37 CFR 1.750 | 25 Apr, 2024 | US7687488 |
Payment of Maintenance Fee, 12th Year, Large Entity | 22 Sep, 2021 | US7687488 |
Patent Issue Date Used in PTA Calculation
Critical
| 21 Sep, 2021 | US11124526 |
Recordation of Patent Grant Mailed
Critical
| 21 Sep, 2021 | US11124526 |
Email Notification
Critical
| 02 Sep, 2021 | US11124526 |
Issue Notification Mailed
Critical
| 01 Sep, 2021 | US11124526 |
Application Is Considered Ready for Issue
Critical
| 18 Aug, 2021 | US11124526 |
Dispatch to FDC | 18 Aug, 2021 | US11124526 |
Issue Fee Payment Received
Critical
| 16 Aug, 2021 | US11124526 |
Issue Fee Payment Verified
Critical
| 16 Aug, 2021 | US11124526 |
Email Notification
Critical
| 17 May, 2021 | US11124526 |
Allecra Theraps's Family Patents
Allecra Theraps Drug List
Given below is the complete list of Allecra Theraps's drugs and the patents protecting them.
1. Exblifep
Exblifep is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US11124526 | Crystalline beta-lactamase inhibitor |
07 Nov, 2034
(10 years from now)
| Active |
US7687488 | 2-substituted methyl penam derivatives |
03 Dec, 2027
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Exblifep's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List